Pioglitazone, an anti-diabetic drug requires sustained MAPK activation for its anti-tumor activity in MCF7 breast cancer cells, independent of PPAR-γ pathway (Q35882837)
Jump to navigation
Jump to search
scientific article published on 20 August 2015
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Pioglitazone, an anti-diabetic drug requires sustained MAPK activation for its anti-tumor activity in MCF7 breast cancer cells, independent of PPAR-γ pathway |
scientific article published on 20 August 2015 |
Statements
1 reference
Pioglitazone, an anti-diabetic drug requires sustained MAPK activation for its anti-tumor activity in MCF7 breast cancer cells, independent of PPAR-γ pathway (English)
1 reference
Labanyamoy Kole
1 reference
Mrinmoy Sarkar
1 reference
Anwesha Deb
1 reference
Biplab Giri
1 reference
20 August 2015
1 reference
1 reference
68
1 reference
1
1 reference
144-154
1 reference
Identifiers
1 reference
1 reference